drugset / Trial / NCT00961441

Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy

NCT00961441

Phase 2 Completed 25 enrolled UCB BIOSCIENCES, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To study how the body absorbs, distributes, metabolises and eliminates Keppra XR in both children (12 to 16 years old) and adults (18 to 55 years old) with epilepsy.

Timeline

Start
2009-09
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 1000 mg
Subject Levetiracetam Other / unclassified 3000 mg

Indications